Navigating the Inflation Reduction Act: Reassessing Evidence and Value Needs for Price Negotiations

The signing of the Inflation Reduction Act (IRA) in 2022 represented one of the most significant landscape changes to the United States health care ecosystem over the past decade. In particular, the provision authorizing Centers for Medicare and Medicaid Services (CMS) to negotiate drug prices has had a major impact on pharmaceutical manufacturers.

On Aug. 15, 2024, CMS released the maximum fair price (MFP) for the first 10 drugs selected for price negotiations, however, detailed rationale for the negotiated prices was not released until March 2025.

The expert panel on this webinar investigated the CMS policy guidance around evidence considered while determining MFPs and offer perspectives regarding evidence strategies that could help manufacturers demonstrate true product value during Medicare price negotiations.

Watch our webinar to explore CMS’ initial policy guidance on evidence leveraged for supporting negotiations with manufacturers and determining MFP, as well as strategies for developing robust evidence packages to be prepared for future Medicare price negotiations.